BofA raised the firm’s price target on Denali Therapeutics (DNLI) to $29 from $26 and keeps a Buy rating on the shares after the company hosted an investor day to outline its three-year growth strategy. Following the event, the firm introduced the royalty agreement with Royalty Pharma into its model and adjusted its cost of goods sold estimates based on management commentary, while also increasing its gross pipeline value to $4.5B from $4B.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNLI:
- Denali Therapeutics price target raised to $31 from $30 at Wedbush
- Denali Therapeutics: Promising Pipeline and Strategic Advancements Justify Buy Rating
- Denali Therapeutics: Promising Future with Strategic Agreements and Innovative Programs
- Denali Therapeutics Secures $275M Royalty Funding Deal
- Denali Therapeutics Hosts Investor Day, Updates Pipeline